CARRIE FOXWORTH: Open Payments
NPI 1972018992 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,448 in 71 payments from 12 companies in 2025. Trend: 2023 $1,492 · 2024 $1,387 · 2025 $1,448
Food & beverage: $1,448
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $250 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $215 |
| Lundbeck LLC | 9 | $196 |
| Neurocrine BioSciences, Inc. | 4 | $142 |
| Vanda Pharmaceuticals Inc. | 5 | $115 |
| Teva Pharmaceuticals USA, Inc. | 5 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $101 |
| E.R. Squibb & Sons, L.L.C. | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 4 | $74 |
| Janssen Pharmaceuticals, Inc | 3 | $71 |
Products named: VRAYLAR, CAPLYTA, REXULTI, INGREZZA, FANAPT, AUSTEDO XR, COBENFY, Qelbree.
Industry payments across MS — which companies pay providers there.
